BCC 2021 | APHINITY: 6-year follow-up results of dual HER2 blockade in HER2+ breast cancer

Martine Piccart, MD, PhD, Université Libre de Bruxelles, Brussels, Belgium, talks on the updated 6-year follow-up results from the Phase III APHINITY trial (NCT01358877) of dual HER2-blockade with pertuzumab and trastuzumab in early HER2-positive breast cancer. The trial enrolled over 4800 patients with node-positive or high-risk node-negative disease and randomized them to receive either pertuzumab or placebo, in combination with standard adjuvant chemotherapy and trastuzumab. The results showed that in patients with node-positive disease, invasive disease-free survival was significantly prolonged in the pertuzumab cohort compared to those receiving placebo. However, no clear benefit was demonstrated in the node-negative cohort. This interview took place during the 17th St. Gallen International Breast Cancer Conference.